Industry Breakfasts are commercially supported educational activities held on the mornings of the main ASM days.  Content of the breakfast sessions is not endorsed by the ANZSN.  By registering for an industry breakfast you are agreeing to the breakfast host receiving your contact details.

*Please note the Advances in Advances in ADPKD breakfast and the SGLT2 inhibitors current state of play breakfast run concurrently on Tuesday morning

Advances in ADPKD – Otsuka Breakfast Symposium

  • Date: Tuesday 11th September
  • Time: 0700-0750
  • Venue: Meeting Room C3.6, International Convention Centre

Breakfast speakers:

A/Prof Ian Fraser (Chair): Clinical experience with tolvaptan in ADPKD

Associate Professor Ian Fraser is a Nephrologist at Royal Melbourne Hospital, and is Director of Internal Medicine for Epworth HealthCare.  He has been actively involved in clinical trials for over 20 years, and has experience in the use of tolvaptan in both Phase III clinical trials and open label studies in autosomal dominant polycystic kidney disease, for approximately 10 years.


Ben Lundie, Principal Scientist at Genome One: Modern genomics

Ben Lundie is Principal Scientist at Genome.One and has over 14 year’s experience in diagnostic genomics. Ben has a Bachelor of Applied Science in Biotechnology and Biomolecular Sciences and a Master of Science in Genetic Counselling. Ben has a background in cytogenetics and for the past decade has worked on the development and implementation of new tests including microarray, PGD/S, NIPT and now clinical whole genome sequencing.


Breakfast will be provided.  Numbers limited.  

SGLT2 inhibitors current state of play – Boehringer Ingelheim and Eli Lilly Breakfast Symposium

  • Date: Tuesday 11th September
  • Time: 0700-0750
  • Venue: Meeting Room C3.4+C3.5, International Convention Centre

Breakfast speaker: Prof Mark Thomas

Dr Mark Thomas trained at Sydney Hospital, RPA and Royal North Shore, then worked in a combined clinical-research position at Guy’s Hospital in London for 3 years, before coming to Royal Perth Hospital as a staff nephrologist in 1988.

He has had an active interest in teaching general medicine and nephrology, which has included nurses, dental and medical students (both urban and rural), AMEC candidates, hospital junior staff, FRACP candidates and fellow nephrologists over the years, as well as many GP educational meetings.

He still works full-time at Royal Perth, with a tiny private practice in Kirkman House, and regular visiting nephrology service to remote areas of Western Australia, first to Kalgoorlie, and now Esperance and the isolated aboriginal community of Tjuntjuntjurra in Spinifex country.

His clinical research interests include kidney disease in Aborigines, diabetic nephropathy, polycystic kidney disease, and the highly specialized problems of loin-pain/haematuria syndrome, and Fabry’s disease, where he runs the Statewide Service. He has published several book chapters, 60 peer-reviewed articles and 97 scientific abstracts.

SGLT2 inhibitors current state of play

The glycosurics and incretins have revolutionised diabetic therapy, exposing just how many previous features of diabetes (hunger, weight-gain, heart failure, sudden death) were medication side-effects rather than the result of patients’ lifestyle choices.

The multi-system effects and benefits of modern diabetic therapy now mandate a new unified collaborative management approach, no longer “gluco-centric”.

Plain English patient & pharmacist education is paramount, both for multi-drug “sick-day plans”, as well as safe transition through the tricky first two months of modern therapy, to avoid precipitating urogenital sepsis, DKA or unmasked critical arterial stenoses.

New hard outcome data is arriving all the time, exploring  the benefits in preventing acute and chronic kidney disease, and primary as well as secondary cardiac events.

Please come and share a few tips, tricks & Thoamasisms.

Download your PDF copy of the invitation here

Breakfast will be provided.  Numbers limited.  

Two companies. One commitment to diabetes. Since 2012, Boehringer Ingelheim and Eli Lilly as an Alliance have brought to market a number of new therapies, based on years of research and development. Supporting multiple international clinical trials, new evidence has been generated to improve the management and outcomes for patients with type 2 diabetes. By partnering with the medical and healthcare community, we will continue to contribute these improvements as two companies, with one commitment to diabetes.


The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd